Literature DB >> 18948405

Regulation of myogenic differentiation by androgens: cross talk between androgen receptor/ beta-catenin and follistatin/transforming growth factor-beta signaling pathways.

Rajan Singh1, Shalender Bhasin, Melissa Braga, Jorge N Artaza, Shehla Pervin, Wayne E Taylor, Venkatesh Krishnan, Satyesh K Sinha, Tripathi B Rajavashisth, Ravi Jasuja.   

Abstract

Androgens are important regulators of body composition and promote myogenic differentiation and inhibit adipogenesis of mesenchymal, multipotent cells. Here, we investigated the mechanisms by which androgens induce myogenic differentiation of mesenchymal multipotent cells. Incubation of mesenchymal multipotent C3H 10T1/2 cells with testosterone and dihydrotestosterone promoted nuclear translocation of androgen receptor (AR)/beta-catenin complex and physical interaction of AR, beta-catenin, and T-cell factor-4 (TCF-4). Inhibition of beta-catenin by small inhibitory RNAs significantly decreased testosterone-induced stimulation of myogenic differentiation. Overexpression of TCF-4, a molecule downstream of beta-catenin in Wnt signaling cascade, in C3H 10T1/2 cells significantly up-regulated expression of myoD and myosin heavy chain II proteins and of follistatin (Fst), which binds and antagonizes native ligands of the TGF-beta/Smad pathway. Gene array analysis of C3H 10T1/2 cells treated with testosterone revealed that testosterone up-regulated the expression of Fst and modified the expression of several signaling molecules involved in the TGF-beta/Smad pathway, including Smad7. Lowering of testosterone levels in mice by orchidectomy led to a significant decrease in Fst and Smad7 expression; conversely, testosterone supplementation in castrated mice up-regulated Fst and Smad7 mRNA expression in androgen-responsive levator ani muscle. Testosterone-induced up-regulation of MyoD and myosin heavy chain II proteins in C3H 10T1/2 cells was abolished in cells simultaneously treated with anti-Fst antibody, suggesting an essential role of Fst during testosterone regulation of myogenic differentiation. In conclusion, our data suggest the involvement of AR, beta-catenin, and TCF-4 pathway during androgen action to activate a number of Wnt target genes, including Fst, and cross communication with the Smad signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18948405      PMCID: PMC2654730          DOI: 10.1210/en.2008-0858

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  50 in total

1.  Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis.

Authors:  Helge Amthor; Gina Nicholas; Iain McKinnell; C Fred Kemp; Mridula Sharma; Ravi Kambadur; Ketan Patel
Journal:  Dev Biol       Date:  2004-06-01       Impact factor: 3.582

2.  Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins.

Authors:  Yisrael Sidis; Abir Mukherjee; Henry Keutmann; Anne Delbaere; Miyuki Sadatsuki; Alan Schneyer
Journal:  Endocrinology       Date:  2006-04-20       Impact factor: 4.736

3.  Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine.

Authors:  S M Taylor; P A Jones
Journal:  Cell       Date:  1979-08       Impact factor: 41.582

4.  Type beta transforming growth factor is an inhibitor of myogenic differentiation.

Authors:  J Massagué; S Cheifetz; T Endo; B Nadal-Ginard
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

Review 5.  Testosterone action on skeletal muscle.

Authors:  Karen L Herbst; Shalender Bhasin
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2004-05       Impact factor: 4.294

6.  Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway.

Authors:  Rajan Singh; Jorge N Artaza; Wayne E Taylor; Nestor F Gonzalez-Cadavid; Shalender Bhasin
Journal:  Endocrinology       Date:  2003-07-24       Impact factor: 4.736

7.  Transforming growth factor-beta. A very potent inhibitor of myoblast differentiation, identical to the differentiation inhibitor secreted by Buffalo rat liver cells.

Authors:  J R Florini; A B Roberts; D Z Ewton; S L Falen; K C Flanders; M B Sporn
Journal:  J Biol Chem       Date:  1986-12-15       Impact factor: 5.157

8.  Androgen receptor immunoreactivity in skeletal muscle: enrichment at the neuromuscular junction.

Authors:  Douglas Ashley Monks; Erin Louise O'Bryant; Cynthia Lee Jordan
Journal:  J Comp Neurol       Date:  2004-05-17       Impact factor: 3.215

9.  TGF-beta-activated Smad3 represses MEF2-dependent transcription in myogenic differentiation.

Authors:  Dong Liu; Jong Seok Kang; Rik Derynck
Journal:  EMBO J       Date:  2004-03-25       Impact factor: 11.598

10.  Transfection of a DNA locus that mediates the conversion of 10T1/2 fibroblasts to myoblasts.

Authors:  A B Lassar; B M Paterson; H Weintraub
Journal:  Cell       Date:  1986-12-05       Impact factor: 41.582

View more
  53 in total

1.  Testosterone inhibits transforming growth factor-β signaling during myogenic differentiation and proliferation of mouse satellite cells: potential role of follistatin in mediating testosterone action.

Authors:  Melissa Braga; Shalender Bhasin; Ravi Jasuja; Shehla Pervin; Rajan Singh
Journal:  Mol Cell Endocrinol       Date:  2011-11-25       Impact factor: 4.102

Review 2.  Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actions.

Authors:  Vanessa Dubois; Michaël Laurent; Steven Boonen; Dirk Vanderschueren; Frank Claessens
Journal:  Cell Mol Life Sci       Date:  2011-11-19       Impact factor: 9.261

3.  Topical androgen antagonism promotes cutaneous wound healing without systemic androgen deprivation by blocking β-catenin nuclear translocation and cross-talk with TGF-β signaling in keratinocytes.

Authors:  Gianluca Toraldo; Shalender Bhasin; Mena Bakhit; Wen Guo; Carlo Serra; Joshua D Safer; Jag Bhawan; Ravi Jasuja
Journal:  Wound Repair Regen       Date:  2012 Jan-Feb       Impact factor: 3.617

Review 4.  Mesenchymal stem cells and the embryonic reawakening theory of BPH.

Authors:  W Nathaniel Brennen; John T Isaacs
Journal:  Nat Rev Urol       Date:  2018-11       Impact factor: 14.432

Review 5.  Nuclear receptor regulation of stemness and stem cell differentiation.

Authors:  Yangsik Jeong; David J Mangelsdorf
Journal:  Exp Mol Med       Date:  2009-08-31       Impact factor: 8.718

6.  Transcriptome analysis of the dihydrotestosterone-exposed fetal rat gubernaculum identifies common androgen and insulin-like 3 targets.

Authors:  Julia S Barthold; Yanping Wang; Alan Robbins; Jack Pike; Erin McDowell; Kamin J Johnson; Suzanne M McCahan
Journal:  Biol Reprod       Date:  2013-12-19       Impact factor: 4.285

7.  Novel strategies for improving physical function.

Authors:  Shalender Bhasin; Ravi Jasuja; Powen Tu; Thomas W Storer; Wen Guo
Journal:  Horm Res Paediatr       Date:  2011-07-21       Impact factor: 2.852

8.  Castration Determines the Efficacy of ETAR Blockade in a Mouse Model of Prostate Cancer Bone Metastasis.

Authors:  Henry H Moon; Katrina L Clines; Mark A Cooks; Charlotte A Cialek; Marian A Esvelt; Gregory A Clines
Journal:  Endocrinology       Date:  2019-08-01       Impact factor: 4.736

9.  Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-β, COX2 and sex steroid receptors.

Authors:  Nicholas A Mignemi; Doha M Itani; John H Fasig; Vicki L Keedy; Kenneth R Hande; Brent W Whited; Kelly C Homlar; Hernan Correa; Cheryl M Coffin; Jennifer O Black; Yajun Yi; Jennifer L Halpern; Ginger E Holt; Herbert S Schwartz; Jonathan G Schoenecker; Justin M M Cates
Journal:  Cancer Sci       Date:  2012-11-15       Impact factor: 6.716

Review 10.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.